Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Techne (TECH) EBITDA Margin (2016 - 2025)

Bio-Techne (TECH) has 17 years of EBITDA Margin data on record, last reported at 13.54% in Q4 2025.

  • For Q4 2025, EBITDA Margin rose 1040.0% year-over-year to 13.54%; the TTM value through Dec 2025 reached 8.59%, down 279.0%, while the annual FY2025 figure was 7.53%, 592.0% down from the prior year.
  • EBITDA Margin reached 13.54% in Q4 2025 per TECH's latest filing, up from 11.75% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 3647.25% in Q3 2022 and bottomed at 1.42% in Q2 2025.
  • Average EBITDA Margin over 5 years is 197.04%, with a median of 14.49% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: skyrocketed 362293bps in 2022, then tumbled -363315bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 31.53% in 2021, then decreased by -22bps to 24.56% in 2022, then tumbled by -38bps to 15.34% in 2023, then plummeted by -80bps to 3.14% in 2024, then soared by 331bps to 13.54% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 13.54% in Q4 2025, 11.75% in Q3 2025, and 1.42% in Q2 2025.